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Purpose:
IARCT has played a major role in targeted treatment of head and neck cancers due to the 
increased intratumoral drug concentrations achieved with this approach. It is proposed that super-
selective IACRT may become primary therapy for external ear canal tumours due to its safety 
profile. However, the efficacy and benefits of IACRT over conventional surgery and radiotherapy 
for the treatment of early external auditory canal tumours has not been systematically determined. 
The objective of this review is to analyse the results from studies involving IACRT, compare them 
to clinical studies with surgery and radiotherapy as primary treatment modalities and perform a 
pooled analysis on the relative efficacy of IACRT
Methods
Systematic literature searches were performed to identify clinical studies reporting treatment of ex-
ternal auditory canal tumors. A comprehensive search of electronic databases (i.e Web of Science, 
Medline, SCOPUS, Cochrane), using broad search terms, was completed. All studies involving IA 
chemoradiotherapy were included, and all studies with conventional therapeutic modalities were 
collated and analysed separately. Parameters analysed were overall disease free survival over a 
minimum of 2 years. In all 4 studies on IACRT, only patients with locally advanced tumours were 
treated. In order to gain a fair comparison, only studies on conventional therapy that included 
locally advanced tumours were reviewed
Results
In the sum of 4 clinical studies, there were a total of 38 patients that were treated with super-
selective IACRT. The cumulative results from for studies showed a mean survival rate of 60.75% 
over the period of 2 years. This is superior to the mean 2 year DFS of patients who were treated 
with conventional therapy which was 41.2% for locally advanced cancers.
Conclusion
IACRT has been shown to be relatively superior to conventional therapy with respect to mean 
survival rate for locally advanced EAC tumour, with less postulated toxic side effects. However, 
more studies are needed to demonstrate this as there currently only 4 recent studies on IACRT, 
and all of which were performed in Japan. Proof of efficacy in locally advanced EAC tumours might 
encourage trials in early EAC tumours. 
